Expand your dosing alternatives with 2 effective dosage strengths

The 20 mg therapeutic dose deserve to be reached in 8 days1
*
*

Tablets displayed are not actual size.

You are watching: Can you cut viibryd tablets in half

†Based top top individual patient efficacy and also tolerability, the dose might be boosted up to 40 mg once everyday with food after a minimum of 7 days between dosage increases.1


Viibryd® should be taken v food1

taking Viibryd top top an north stomach can reduce plasma concentration (AUC) by around 50% and also may diminish effectiveness
If a dose is missed, it have to be bring away as shortly as the patient remembers. If it is practically time for the next dose, the patient have to skip the missed dose and take the next dose in ~ the consistent time. 2 doses should not be taken at the same time. Before initiating treatment through Viibryd, display screen patients because that a personal or family background of bipolar disorder, mania, or hypomania. Adverse reactions may happen upon discontinuation that Viibryd. Steady dose reduction fairly than abrupt cessation is encourage whenever possible. Viibryd should be tapered from the 40 mg once day-to-day dose to 20 mg once daily for 4 days, adhered to by 10 mg once everyday for 3 days. Patients acquisition Viibryd 20 mg once day-to-day should it is in tapered to 10 mg once everyday for 7 days.

No dose adjustment is recommended because that a variety of populations1

No sheep adjustment necessary based on age or gender1 No dose adjustment necessary for patients with renal impairment1 No dose adjustment necessary for patients with hepatic impairment1

Drug Interactions

The Viibryd dose must not exceed 20 mg once daily if co-administered with strong CYP3A4 inhibitors (eg, itraconazole, clarithromycin, voriconazole). The original Viibryd dose level deserve to be resumed as soon as the CYP3A4 inhibitor is discontinued. Based on clinical response, think about increasing Viibryd sheep by 2-fold (up to a maximum 80 mg when daily) end 1 come 2 weeks as soon as taking strong CYP3A4 inducers (eg, carbamazepine, phenytoin, rifampin) for higher than 14 days. If CYP3A4 inducers are discontinued, gradually reduce Viibryd sheep to original level end 1 to 2 weeks. At least 14 days should elapse in between discontinuation of one MAOI antidepressant and initiation that Viibryd. In addition, at the very least 14 days have to elapse after stopping Viibryd before beginning an MAOI antidepressant. Do not begin Viibryd in a patient who is gift treated through linezolid or intravenous methylene blue due to the fact that there is an raised risk the serotonin syndrome. Concomitant use of Viibryd through NSAIDs, aspirin, warfarin, and also other anticoagulants may boost the hazard of bleeding events. Concomitant use of Viibryd boosted digoxin concentrations. Measure up serum digoxin concentrations prior to initiating concomitant usage of Viibryd. Continue monitoring and reduce digoxin dose as necessary. usage in details Populations There space no adequate and well-controlled studies of Viibryd in pregnant women. Think about the dangers of untreated depression once discontinuing or transforming treatment v antidepressant medication during pregnancy and postpartum. Exposure to SSRIs and SNRIs, including Viibryd, in late pregnancy may lead to an raised risk for neonatal complications requiring an extensive hospitalization, respiratory support, and also tube feeding, and/or persistent pulmonary hypertension of the newborn (PPHN). Monitor neonates who were exposed come Viibryd in the 3rd trimester of pregnant for PPHN and drug discontinuation syndrome. There room no data ~ above the presence of vilazodone in human milk, the effects of vilazodone on the breastfed infant, or the impacts of the medicine on milk production. However, vilazodone is excreted in rat milk. The developmental and also health benefits of breastfeeding must be considered together with the mom clinical require for Viibryd and also any potential adverse effects on the breastfed kid from Viibryd or from the basic maternal condition.

Next: system of action ►


VIIBRYD (vilazodone HCI) is indicated for the therapy of significant depressive disorder (MDD) in adults.


WARNING: SUICIDAL THOUGHTS and BEHAVIORS

Antidepressants boosted the hazard of suicidal thoughts and also behaviors in pediatric and young adult patients in momentary studies. Closely monitor every antidepressant-treated patients because that clinical worsening and also for appearance of suicidal thoughts and also behaviors. VIIBRYD is not approved for usage in pediatric patients.


Contraindications

VIIBRYD is contraindicated in patient taking, or within 14 days of stopping, monoamine oxidase inhibitors (MAOIs), consisting of MAOIs such together linezolid or intravenous methylene blue, since of an raised risk that serotonin syndrome.

Warnings and Precautions

Suicidal Thoughts and Behavior in adolescents and Young Adults: Monitor every antidepressant-treated patients because that clinical worsening and also emergence the suicidal thoughts and also behaviors, especially during the initial few months the treatment and when changing the dose. Counsel family members members or caregivers of patient to monitor for alters in behavior and to alert the health care provider. Consider changing the therapeutic regimen, including possibly discontinuing VIIBRYD, in patients whose depression is persistently worse, or who are experiencing emergent suicidal think or behaviors. Serotonin Syndrome: Serotonin and also norepinephrine reuptake inhibitors (SNRIs) and also selective serotonin reuptake inhibitors (SSRIs), including VIIBRYD, can cause a perhaps life-threatening problem called serotonin syndrome when taken alone, but especially when supplied concomitantly with other serotonergic agents (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, amphetamines, and St. John’s Wort) and also with drugs that impair management of serotonin, ie, MAOIs. Symptoms of serotonin syndrome were noted in 0.1% the VIIBRYD-treated patient in premarketing clinical trials. Serotonin syndrome signs and symptoms may include mental status alters (eg, agitation, hallucinations, delirium, and coma), autonomic instability (eg, tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular symptom (eg, tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, and gastrointestinal symptoms. Monitor every patients taking VIIBRYD because that the introduction of serotonin syndrome. If symptom occur, discontinue VIIBRYD and also any concomitant serotonergic agents immediately and also initiate donate treatment. If concomitant usage of VIIBRYD with other serotonergic medicine is clinically warranted, inform patients of the increased risk because that serotonin syndrome. increased Risk the Bleeding: Drugs the interfere through serotonin reuptake inhibition, consisting of VIIBRYD, rise the danger of bleeding events. Educate patients about the included risk the bleeding linked with the concomitant use of VIIBRYD and also aspirin, NSAIDs, various other antiplatelet drugs, warfarin, or various other anticoagulants. For patients taking warfarin, closely monitor coagulation indices as soon as initiating, titrating, or discontinuing VIIBRYD. Activation of Mania/Hypomania: dealing with a depressive episode v VIIBRYD or an additional antidepressant in a patient with bipolar disorder may precipitate a mixed/manic episode. In controlled clinical trials, patients with bipolar disorder to be excluded; however, symptoms of mania/hypomania were listed in 0.1% of undiagnosed patient treated v VIIBRYD. Before initiating VIIBRYD, display patients for any personal or family history of bipolar disorder, mania, or hypomania. VIIBRYD is no approved for use in dealing with bipolar depression. Discontinuation Syndrome: adverse reactions may occur upon discontinuation of serotonergic antidepressants such as VIIBRYD, an especially after abrupt discontinuation. Gradual dose palliation is recommended, instead of abrupt cessation, anytime possible. Seizures: VIIBRYD should be prescribed with caution in patients v a seizure disorder. Angle-Closure Glaucoma: The pupillary dilation the occurs adhering to use of many antidepressants, consisting of VIIBRYD, may create an angle closure strike in a patient v anatomically small angles that does not have a patent iridectomy. Avoid use that VIIBRYD in patients with untreated anatomically narrow angles. Hyponatremia: Hyponatremia may occur from treatment with SNRIs and also SSRIs, including VIIBRYD. Yonsei patients, patients taking diuretics, and also those who are volume-depleted might be at better risk of emerging hyponatremia while acquisition VIIBRYD. In patients v symptomatic hyponatremia, discontinue VIIBRYD and also institute ideal medical intervention.

adverse Reactions

The most generally observed disadvantage reactions through VIIBRYD in 8- come 10-week placebo-controlled researches (incidence ≥5% and at the very least twice the price of placebo) by sheep (20 mg, 40 mg) vs placebo were: diarrhea (26%, 29% vs 10%), nausea (22%, 24% vs 7%), insomnia (7%, 6% vs 2%), and also vomiting (4%, 5% vs 2%).

Please also see the full Prescribing Information.

See more: Costco Pizza Calories In One Slice Of Costco Pizza, Costco Pizza Calories & Nutrition Facts (Chart)


*

For added information about VIIBRYD, speak to AbbVie Medical info toll-free at 800-678-1605. VIIBRYD® and its architecture are registered trademarks that Allergan Sales, LLC, an AbbVie company. © 2020 AbbVie. All legal rights reserved. The information noted in this site is plan for us healthcare experts only. The assets described top top this site might have various product labeling in nations outside that the unified States.

VBD92402-v912/20


WARNING: SUICIDAL THOUGHTS and also BEHAVIORS

Antidepressants boosted the risk of suicidal thoughts and behaviors in pediatric and also young adult patient in short-term studies. Very closely monitor every antidepressant-treated patients because that clinical worsening and also for development of suicidal thoughts and also behaviors. VIIBRYD is not approved for use in pediatric patients.


Contraindications

VIIBRYD is contraindicated in patients taking, or within 14 work of stopping, monoamine oxidase inhibitors (MAOIs), consisting of MAOIs such as linezolid or intravenous methylene blue, due to the fact that of an boosted risk that serotonin syndrome.

Warnings and Precautions

Suicidal Thoughts and Behavior in teens and Young Adults: Monitor all antidepressant-treated patients for clinical worsening and also emergence that suicidal thoughts and also behaviors, especially throughout the initial couple of months the treatment and when transforming the dose. Counsel family members members or caregivers of patients to monitor for transforms in behavior and also to alarm the health care provider. Consider an altering the therapeutic regimen, consisting of possibly discontinuing VIIBRYD, in patients whose depression is persistently worse, or who space experiencing emergent suicidal thoughts or behaviors. Serotonin Syndrome: Serotonin and norepinephrine reuptake inhibitors (SNRIs) and selective serotonin reuptake inhibitors (SSRIs), consisting of VIIBRYD, can cause a perhaps life-threatening problem called serotonin syndrome when taken alone, yet especially when used concomitantly with various other serotonergic agents (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, amphetamines, and also St. John’s Wort) and with drugs that impair management of serotonin, ie, MAOIs. Symptom of serotonin syndrome were listed in 0.1% that VIIBRYD-treated patients in premarketing clinical trials. Serotonin syndrome signs and also symptoms may incorporate mental status transforms (eg, agitation, hallucinations, delirium, and also coma), autonomic instability (eg, tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (eg, tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, and also gastrointestinal symptoms. Monitor every patients taking VIIBRYD for the emergence of serotonin syndrome. If symptom occur, discontinue VIIBRYD and any concomitant serotonergic agents immediately and initiate donate treatment. If concomitant usage of VIIBRYD with various other serotonergic drugs is clinically warranted, educate patients that the increased risk for serotonin syndrome. boosted Risk the Bleeding: Drugs that interfere through serotonin reuptake inhibition, consisting of VIIBRYD, boost the threat of bleeding events. Notify patients around the added risk of bleeding associated with the concomitant use of VIIBRYD and aspirin, NSAIDs, other antiplatelet drugs, warfarin, or various other anticoagulants. Because that patients taking warfarin, very closely monitor coagulation indices when initiating, titrating, or discontinuing VIIBRYD. Activation the Mania/Hypomania: dealing with a depressive episode v VIIBRYD or another antidepressant in a patient through bipolar disorder may precipitate a mixed/manic episode. In regulated clinical trials, patients with bipolar disorder were excluded; however, symptoms of mania/hypomania were provided in 0.1% that undiagnosed patient treated through VIIBRYD. Before initiating VIIBRYD, screen patients because that any personal or family history of bipolar disorder, mania, or hypomania. VIIBRYD is not approved for usage in treating bipolar depression. Discontinuation Syndrome: disadvantage reactions may occur upon discontinuation of serotonergic antidepressants such together VIIBRYD, specifically after abrupt discontinuation. Progressive dose reduction is recommended, instead of abrupt cessation, whenever possible. Seizures: VIIBRYD must be prescribed with caution in patients through a seizure disorder. Angle-Closure Glaucoma: The pupillary dilation that occurs following use of numerous antidepressants, consisting of VIIBRYD, may trigger an angle closure assault in a patient through anatomically small angles who does not have actually a patent iridectomy. Protect against use that VIIBRYD in patients v untreated anatomically small angles. Hyponatremia: Hyponatremia may take place from treatment v SNRIs and SSRIs, including VIIBRYD. Yonsei patients, patients acquisition diuretics, and also those who room volume-depleted might be at higher risk of arising hyponatremia while acquisition VIIBRYD. In patients through symptomatic hyponatremia, discontinue VIIBRYD and institute proper medical intervention.

disadvantage Reactions

The most typically observed adverse reactions through VIIBRYD in 8- come 10-week placebo-controlled studies (incidence ≥5% and also at the very least twice the price of placebo) by sheep (20 mg, 40 mg) vs placebo were: diarrhea (26%, 29% vs 10%), nausea (22%, 24% vs 7%), insomnia (7%, 6% vs 2%), and also vomiting (4%, 5% vs 2%).

Please additionally see the complete Prescribing Information.